Saeed Aamir, Khan Mumtaz, Morrissey Siobhan, Kane David, Fraser Alexander Duncan
Department of Rheumatology, Adelaide and Meath Hospital, Tallaght, Dublin 24, Ireland,
Rheumatol Int. 2014 Apr;34(4):503-9. doi: 10.1007/s00296-013-2892-z. Epub 2013 Nov 5.
The use of musculoskeletal ultrasonography (MSUS) in guiding subdeltoid injection has been shown to improve outcome up to 6 weeks in a few small studies. A recent meta-analysis identified the need for further studies with longer-term outcome and larger sample size. This randomized prospective study assessed whether clinic-based MSUS can significantly improve diagnostic accuracy in shoulder pain and whether MSUS-guided shoulder injection results in improved long-term outcomes. One hundred consecutive patients with 125 painful shoulders were recruited. Patients were randomized to receive either sonographic assessment with consequent palpation-guided injection (Group 1, n = 66) or sonographic assessment with a MSUS-guided injection of 40 mg of methylprednisolone acetate (Group 2, n = 59). A blinded rheumatologist (ADF) performed clinical assessments at baseline, 6 and 12 weeks including shoulder function tests (SFTs) (Hawkins-Kennedy test, supraspinatus tendon tenderness), physician global assessment (PGA) and patient visual analogue scores (VAS) for pain (0-10). Eighty patients with 90 symptomatic shoulders completed 12-week follow-up. Twenty patients, 11 (20 shoulders) from the palpation-guided group and 9 (15 shoulders) from the MSUS-guided group, were excluded at 6 weeks either due to requirement for repeat injection or due to surgical referral. Mean age for patients was 57.7 years, and 65 % patients were female; mean shoulder pain duration was 18 weeks (range 14-22 weeks). SFTs, patient VAS and PGA scores for pain improved significantly from baseline in both groups with significantly greater improvements in the MSUS-guided group (44 shoulders) compared to the palpation-guided group (46 shoulders) in all parameters at 6 (p < 0.01) and 12 weeks (p < 0.05). The use of MSUS in guiding subdeltoid injection has been shown to improve outcome up to 6 weeks in a few small studies. A recent meta-analysis identified the need for further studies with longer-term outcome and larger sample size.
在一些小型研究中,已表明使用肌肉骨骼超声检查(MSUS)引导三角肌下注射可在长达6周的时间内改善治疗效果。最近的一项荟萃分析指出,需要开展更多关于长期治疗效果及更大样本量的研究。这项随机前瞻性研究评估了基于临床的MSUS是否能显著提高肩部疼痛的诊断准确性,以及MSUS引导下的肩部注射是否能带来更好的长期治疗效果。研究招募了100例连续患者,共125个疼痛肩部。患者被随机分为两组,一组接受超声评估并随后进行触诊引导注射(第1组,n = 66),另一组接受超声评估并在MSUS引导下注射40mg醋酸甲泼尼龙(第2组,n = 59)。一位盲法风湿病学家(ADF)在基线、6周和12周时进行临床评估,包括肩部功能测试(SFTs)(霍金斯 - 肯尼迪试验、冈上肌腱压痛)、医生整体评估(PGA)以及患者疼痛视觉模拟评分(VAS)(0 - 10分)。80例患者共90个有症状的肩部完成了12周的随访。20例患者,其中触诊引导组11例(20个肩部),MSUS引导组9例(15个肩部),在6周时因需要重复注射或手术转诊而被排除。患者的平均年龄为57.7岁,65%为女性;平均肩部疼痛持续时间为18周(范围14 - 22周)。两组的SFTs、患者VAS和PGA疼痛评分均较基线有显著改善,在6周(p < 0.01)和12周(p < 0.05)时,MSUS引导组(44个肩部)在所有参数上的改善均显著大于触诊引导组(46个肩部)。在一些小型研究中,已表明使用MSUS引导三角肌下注射可在长达6周的时间内改善治疗效果。最近的一项荟萃分析指出,需要开展更多关于长期治疗效果及更大样本量的研究。